These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26476376)

  • 1. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
    Zhang E; Kosinska A; Lu M; Yan H; Roggendorf M
    Antiviral Res; 2015 Nov; 123():193-203. PubMed ID: 26476376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck.
    Kosinska AD; Liu J; Lu M; Roggendorf M
    Med Microbiol Immunol; 2015 Feb; 204(1):103-14. PubMed ID: 25535101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies.
    Isorce N; Lucifora J; Zoulim F; Durantel D
    Antiviral Res; 2015 Oct; 122():69-81. PubMed ID: 26275801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model.
    Roggendorf M; Schulte I; Xu Y; Lu M
    J Viral Hepat; 2007 Nov; 14 Suppl 1():51-7. PubMed ID: 17958643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antivirals for the treatment of chronic hepatitis B.
    Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure.
    Chang J; Guo JT
    Antiviral Res; 2015 Sep; 121():152-9. PubMed ID: 26205674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
    Kennedy EM; Kornepati AV; Cullen BR
    Antiviral Res; 2015 Nov; 123():188-92. PubMed ID: 26476375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis B: A wave of new therapies on the horizon.
    Block TM; Rawat S; Brosgart CL
    Antiviral Res; 2015 Sep; 121():69-81. PubMed ID: 26112647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aiming for cure in HBV and HDV infection.
    Petersen J; Thompson AJ; Levrero M
    J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune balance in Hepatitis B Infection: Present and Future Therapies.
    Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N
    Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.
    Roggendorf M; Kosinska AD; Liu J; Lu M
    Cold Spring Harb Perspect Med; 2015 Oct; 5(12):. PubMed ID: 26511761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.
    Gish RG; Given BD; Lai CL; Locarnini SA; Lau JY; Lewis DL; Schluep T
    Antiviral Res; 2015 Sep; 121():47-58. PubMed ID: 26092643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.